Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 8/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.74 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.74 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | SCN1A | P35498 | 2/20 | 0.51 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.51 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metocinium SCHEMBL2732726 | 0.98 | CHRM2 (0.72) | CHRM2CHRM1CHRM3CHRM4MEN1 | |
| Methylbenactyzium SCHEMBL669744 | 0.86 | CHRM1 (0.97) | CHRM2CHRM1CHRM3CHRM4MEN1 | |
| Methylbenactyzium SCHEMBL60901 | 0.85 | CHRM1 (1.00) | CHRM2CHRM1CHRM3CHRM4MEN1 | |
| Lachesine SCHEMBL1946024 | 0.85 | CHRM1 (0.75) | CHRM2CHRM1CHRM3CHRM4MEN1 | |
| Methylbenactyzium SCHEMBL8816404 | 0.85 | CHRM1 (0.94) | CHRM2CHRM1CHRM3CHRM4MEN1 | |
| SCHEMBL11363962 | 0.84 | CHRM2 (0.55) | CHRM2CHRM1CHRM3CHRM4MEN1 | |
| SCHEMBL8309422 | 0.84 | CHRM2 (0.60) | CHRM2CHRM1CHRM3CHRM4SCN1A | |
| Lachesine SCHEMBL3638169 | 0.84 | CHRM1 (0.73) | CHRM2CHRM1CHRM3CHRM4MEN1 | |
| SCHEMBL11363241 | 0.83 | CHRM2 (0.57) | CHRM2CHRM1CHRM3CHRM4MEN1 | |
| Methylbenactyzium SCHEMBL8446490 | 0.83 | CHRM1 (0.95) | CHRM2CHRM1CHRM3CHRM4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-3654964-B1 | COMPOSITION COMPRISING ATROPINE AND A MIOTIC AGENT AND ITS USE IN THE TREATMENT OF MYOPIA | SEINDA PHARMACEUTICAL GUANGZHOU CORP (CN) | 2024-04-24 | — | — | EP | disclosed |
| US-20230062844-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYOPIA | Seinda Pharmaceutical Guangzhou Corporation (CN) | 2023-03-02 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200163951-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYOPIA | Seinda Pharmaceutical Guangzhou Corporation (CN) | 2020-05-28 | — | — | US | disclosed |
| EP-3654964-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYOPIA | Alan Laboratories, Inc. (US) | 2020-05-27 | — | — | EP | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-7905852-B2 | Skin-contacting-adhesive free dressing | JENNINGS-SPRING BARBARA | 2011-03-15 | — | — | US | disclosed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | disclosed |
| WO-2010024870-A1 | SKIN-CONTACTING-ADHESIVE FREE DRESSING | JENNINGS-SPRING BARBARA BROOKE (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20090005722-A1 | Skin-contacting-adhesive free dressing | JENNLNGS-SPRING BARBARA | 2009-01-01 | — | — | US | disclosed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163951-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYOPIA | CHRM3, CHRM2, MYOC | CHRM2 2/4885CHRM1 13/4885CHRM3 1/4885 |
| US-20230062844-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYOPIA | CHRM3, CHRM2, MYOC | CHRM2 2/4885CHRM1 13/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.